NCT00436995View on ClinicalTrials.gov

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

PHASE3CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

December 31, 2008

Conditions

Chronic Kidney Disease

Interventions

DRUG

Darbepoetin Alfa

Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.